摘要
目的：探讨肿瘤标志物人附睾蛋白4（HE4）、糖类抗原125（CM25）、人绒毛膜促性腺激素β亚基（β-HCG）和CEA联合检测在卵巢肿瘤中的诊断价值.方法：应用电化学发光全自动免疫分析仪检测102例诊断为卵巢肿瘤的患者,其中卵巢恶性肿瘤患者33例（卵巢癌组）,卵巢良性肿瘤患者69例（卵巢良性肿瘤组）及70例健康女性（健康对照组）的血清HE4、CA125、β-HCG和CEA水平并对结果进行比较分析.结果：卵巢癌组患者HE4、CA125、β-HCG和CEA的水平显著高于卵巢良性肿瘤组和健康对照组,差异具有统计学意义（P＜0.05）;且四者进行联合检测的阳性率均显著高于单项检测的阳性率,差异有统计学意义（P＜0.05）.结论：HE4、CA125、β-HCG和CEA联合检测对于卵巢恶性肿瘤的诊断价值优于单一任何一种肿瘤标志物,有效的联合检测可提高对卵巢癌诊断的敏感性和准确性.
Objective ： To study the value of combinedtumor markers humanepididymis protein 4 （HE4）, carbohydrate antigen 125 （CA125）, human chorionic gonadotropin β subunits （β-HCG） and CEA use in ovarian tumors diagnosis. Methods ： To test 102 patients diagnosed as ovarian tumor with electrochemical luminescence automatic immunity analyzer, including 33 patients with ovarian malignant tumor （ovarian cancer group） and 69 patients with ovarian benign tumors, （ovarian benign tumor group） and 70 cases of healthy women （control group） health serum HE4, CA125, β-HCG and CEA levels and the results were compared.Results ： Govarian cancer group＇ s HE4, CA125, β-HCG and CEA levels significantly higher than ovarian benign tumor group and control group, and a statistically significant differences （P〈0.05）;And positive rate of joint detectionwere significantly higher than that of single detection positive rate, the difference was statistically significant （P〈0. 05）. Conclusions ： The value of combined HE4, CA125, β -HCG and CEA test inovarian tumors diagnosis is better than any single kind of tumor markers and effective joint detection can improve the sensitivity and accuracy of diagnosis of ovarian carcinoma.
出处
《医学检验与临床》
2014年第4期45-47,20,共4页
Medical Laboratory Science and Clinics
